Regulation in hemostasis and thrombosis: Part i - In vitro diagnostics

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 3, 2013, Pages 235-249

  Favaloro, Emmanuel J ^a   Plebani, Mario ^b   Lippi, Giuseppe ^c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c Academic Hospital of Parma   (Italy)

Author keywords

diagnostic practice; harmonization; hemostasis testing; in vitro diagnostics; IVDs; regulation; standardization

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; CARDIOLIPIN ANTIBODY; COLLAGEN; COUMARIN DERIVATIVE; RISTOCETIN; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; COMPLEMENT FIXATION TEST; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEMOSTASIS; HUMAN; IMMUNE FUNCTION TEST; IMMUNOASSAY; IN VITRO DIAGNOSTIC; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDIZATION; THROMBOCYTE; THROMBOSIS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR COLLAGEN BINDING ASSAY;

DIAGNOSTIC TESTS, ROUTINE; HEMOSTASIS; HUMANS; THROMBOSIS;

EID: 84875479997     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1336833     Document Type: Article

References (94)

1. Lippi G., Favaloro E. J., Franchini M., Guidi G. C. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost: 2009; 35 1 9 22
2. Favaloro E. J., Lippi G. Coagulation update: what's new in hemostasis testing? Thromb Res: 2011; 127 02 S13 S16
3. Lippi G., Favaloro E. J. Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med: 2013; 51 1 91 97
4. Lippi G., Mattiuzzi C. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics. Clin Chem Lab Med: 2013; 51 2 243 245
5. Lippi G., Simundic A. M. Laboratory networking and sample quality: a still relevant issue for patient safety. Clin Chem Lab Med: 2012; 50 10 1703 1705
6. Adams O., Cooper G., Fraser C., et al. Collective opinion paper on findings of the 2011 convocation of experts on laboratory quality. Clin Chem Lab Med: 2012; 50 9 1547 1558
7. Sédille-Mostafaie M., Engler H., Lutz S., Korte W. Advancing haemostasis automation - successful implementation of robotic centrifugation and sample processing in a tertiary service hospital. Clin Chem Lab Med: 2013; 10.1515/cclm-2012-0625
8. Favaloro E. J., Mohammed S., Pati N., Ho M. Y., McDonald D. A clinical audit of congenital thrombophilia investigation in tertiary practice. Pathology: 2011; 43 3 266 272
9. Favaloro E. J., Reben R., Mohammed S., Koutts J. Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations. Intern Med J: 2012; 42 4 427 434
10. Favaloro E. J., McDonald D. Futility of testing for factor V Leiden. Blood Transfus: 2012; 10 3 260 263
11. Favaloro E. J., Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med: 2011; 49 5 755 757
12. Favaloro E. J., Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb): 2012; 22 3 329 341
13. Favaloro E. J., Lippi G., Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology: 2011; 43 7 682 692
14. Samama M. M., Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med: 2011; 49 5 761 772
15. Tripodi A., Di Iorio G., Lippi G., Testa S., Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL. Clin Chem Lab Med: 2012; 50 12 2137 2140
16. Harenberg J., Giese C., Marx S., Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost: 2012; 38 1 16 22
17. Harenberg J., Erdle S., Marx S., Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost: 2012; 38 2 178 184
18. Harenberg J., Du S., Krämer S., et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point of care testing and urine samples. Semin Thromb Hemost: 2013; 39 1 66 71
19. Favaloro E. J., Plebani M., Lippi G. Quality in hemostasis and thrombosis-part I. Semin Thromb Hemost: 2012; 38 6 549 552
20. Hughes S. Lab automation services. J Lab Autom: 2012; 17 6 405 407
21. van Geffen M., van Heerde W. L. Global haemostasis assays, from bench to bedside. Thromb Res: 2012; 129 6 681 687
22. Lippi G., Plebani M. Continuous-flow automation and hemolysis index: a crucial combination. J Lab Autom: 2012; 10.1177/2211068212450014
23. Barletta G., Zaninotto M., Faggian D., Plebani M. Shop for quality or quantity? Volumes and costs in clinical laboratories. Clin Chem Lab Med: 2013; 51 2 295 301
24. Zaninotto M., Plebani M. The "hospital central laboratoryo": automation, integration and clinical usefulness. Clin Chem Lab Med: 2010; 48 7 911 917
25. Favaloro E. J. Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations. Semin Thromb Hemost: 2007; 33 3 290 297 (Pubitemid 46581384)
26. International organization for Standardization ISO 17511: 2003. In vitro medical devices-measurement of quantities in biological samples-metrological traceability of values assigned to calibrators and controls. Geneva, Switzerland: 2003
27. Siekmann L. Metrological traceability - a concept for standardization in laboratory medicine. Clin Chem Lab Med: 2013; 10.1515/cclm-2012-0710
28. Olson J. D., Preston F. E., Nichols W. L. External quality assurance in thrombosis and hemostasis: an international perspective. Semin Thromb Hemost: 2007; 33 3 220 225 (Pubitemid 46581375)
29. Favaloro E. J., Plebani M., Lippi G. Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing? Clin Chem Lab Med: 2011; 49 12 1965 1973
30. Favaloro E. J. Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country? Pathology: 2011; 43 4 397 402
31. Favaloro E. J. Harmonising quality to the lowest clinical diagnostic standard? The case against regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories. Australian Journal of Medical Science: 2010; 31 56 64
32. Sadler J. E., Budde U., Eikenboom J. CJ., et al. Working Party on von Willebrand Disease Classification Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost: 2006; 4 10 2103 2114 (Pubitemid 44403432)
33. Nichols W. L., Hultin M. B., James A. H., et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia: 2008; 14 2 171 232 (Pubitemid 351343618)
34. Favaloro E. J. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost: 2011; 37 5 440 455
35. Favaloro E. J. New developments in the diagnosis and treatment of von Willebrand disease. Clin Investig: 2012; 2 8 781 795
36. Favaloro E. J. Rethinking the diagnosis of von Willebrand disease. Thromb Res: 2011; 127 02 S17 S21
37. Favaloro E. J., Franchini M., Lippi G. Biological therapies for von Willebrand disease. Expert Opin Biol Ther: 2012; 12 5 551 564
38. Favaloro E. J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost: 2007; 33 8 727 744 (Pubitemid 351158442)
39. Favaloro E. J. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost: 2009; 35 1 60 75
40. Favaloro E. J. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis: 2011; 22 7 553 564
41. Favaloro E. J., Bonar R., Chapman K., Meiring M., Adcock D. F. Differential sensitivity of von Willebrand factor 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen binding and monoclonal antibody based assays. J Thromb Haemost: 2012; 10 6 1043 1054
42. Favaloro E. J., Bonar R., Kershaw G., et al. Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program. Semin Thromb Hemost: 2006; 32 5 505 513 (Pubitemid 44157389)
43. Favaloro E. J., Bonar R., Kershaw G., et al. Royal College Of Pathologists Of Australasia Quality Assurance Program In Haematology Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates. Lab Hematol: 2005; 11 2 91 97 (Pubitemid 40975550)
44. Hayes T. E., Brandt J. T., Chandler W. L., et al. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost: 2006; 32 5 499 504 (Pubitemid 44157388)
45. Meijer P., Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost: 2006; 32 5 485 491 (Pubitemid 44157386)
46. Kitchen S., Jennings I., Woods T. A., Kitchen D. P., Walker I. D., Preston F. E. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost: 2006; 32 5 492 498 (Pubitemid 44157387)
47. Chandler W. L., Peerschke E. IB, Castellone D. D., Meijer P. NASCOLA Proficiency Testing Committee Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol: 2011; 135 6 862 869
48. Favaloro E. J., Bonar R., Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci: 2008; 21 3 178 183
49. Flood V. H., Friedman K. D., Gill J. C., et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost: 2009; 7 11 1832 1839
50. Flood V. H., Gill J. C., Morateck P. A., et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood: 2010; 116 2 280 286
51. Miller C. H., Haff E., Platt S. J., et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost: 2003; 1 10 2191 2197
52. Flood V. H., Lederman C. A., Wren J. S., et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost: 2010; 8 6 1431 1433
53. Hampshire D. J., Goodeve A. C. The international society on thrombosis and haematosis von Willebrand disease database: an update. Semin Thromb Hemost: 2011; 37 5 470 479
54. Adcock D. M., Bethel M., Valcour A. Diagnosing von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost: 2006; 32 5 472 479 (Pubitemid 44157384)
55. Favaloro E. J., Thom J., Patterson D., et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res: 2009; 123 6 862 868
56. st November 2012
57. Favaloro E. J. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost: 2010; 104 5 1009 1021
58. Ni Y., Nesrallah J., Agnew M., Geske F. J., Favaloro E. J. Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity. Int J Lab Hematol: 2013; 35 2 170 176
59. Favaloro E. J., Adcock D. M. Standardization of the INR: how good is your laboratory's INR and can it be improved? Semin Thromb Hemost: 2008; 34 7 593 603
60. Favaloro E. J., McVicker W., Hamdam S., Hocker N. Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box? Clin Chem Lab Med: 2010; 48 8 1079 1090
61. Clinical and Laboratory Standards Institute Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline. CLSI document H54-A [ISBN 1-56238-580-1]. Wayne, PA Clinical and Laboratory Standards Institute: 2005
62. van den Besselaar A. MHP, Barrowcliffe T. W., Houbouyan-Réveillard L. L., et al. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost: 2004; 2 11 1946 1953 (Pubitemid 40192748)
63. Poller L. Taberner, D A. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol: 1982; 51 3 479 485 (Pubitemid 12045323)
64. Olson J. D., Brandt J. T., Chandler W. L., et al. Laboratory reporting of the international normalized ratio: progress and problems. Arch Pathol Lab Med: 2007; 131 11 1641 1647 (Pubitemid 350077460)
65. Favaloro E. J., Wong R. C. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med: 2011; 49 3 447 461
66. Favaloro E. J., Wong R. CW. The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours? Autoimmunity Highlights: 2010; 1 5 14
67. Miyakis S., Lockshin M. D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
68. Kershaw G., Suresh S., Orellana D., Nguy Y. M. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost: 2012; 38 4 375 384
69. Adams M. Measurement of lupus anticoagulants: an update on quality in laboratory testing. Semin Thromb Hemost: 2013; 39 3 267 271
70. Froom P., Barak M. Testing for lupus anticoagulants-fresh or frozen? Clin Chem Lab Med: 2012; 50 9 1607 1609
71. Harris E. N., Gharavi A. EM, Boey M. L., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet: 1983; 2 8361 1211 1214 (Pubitemid 14229783)
72. Favaloro E. J., Wheatland L., Jovanovich S., Roberts-Thomson P., Wong R. CW. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I-Anticardiolipin and anti-β2- glycoprotein I antibodies. Semin Thromb Hemost: 2012; 38 4 390 403
73. Favaloro E. J. Trials and tribulations in lupus anticoagulant testing. Clin Chem Lab Med: 2013; 51 2 253 256
74. Favaloro E. J., Bonar R., Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II-Lupus anticoagulant. Semin Thromb Hemost: 2012; 38 4 404 411
75. Favaloro E. J., Silvestrini R., Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology: 1999; 31 2 142 147 (Pubitemid 29264060)
76. Reber G., Arvieux J., Comby E., et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hémostase et la Thrombose). Thromb Haemost: 1995; 73 3 444 452
77. Favaloro E. J., Wong R. C., Silvestrini R., McEvoy R., Jovanovich S., Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost: 2005; 31 1 73 84 (Pubitemid 40262140)
78. Wong R. C., Adelstein S., Gillis D., Favaloro E. J. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. Semin Thromb Hemost: 2005; 31 1 39 48 (Pubitemid 40262136)
79. Reber G., Boehlen F., de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Semin Thromb Hemost: 2008; 34 4 340 346
80. Pierangeli S. S., Harris E. N. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is? Semin Thromb Hemost: 2008; 34 4 313 328
81. Lakos G., Favaloro E. J., Harris E. N., et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum: 2012; 64 1 1 10
82. Pierangeli S. S., Favaloro E. J., Lakos G., et al. Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta: 2012; 413 1-2 358 360
83. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood: 2003; 101 5 1827 1832 (Pubitemid 36237580)
84. Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood: 2003; 102 8 2717 2723 (Pubitemid 37248837)
85. Galli M., Reber G., de Moerloose P., de Groot P. G. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost: 2008; 6 2 399 401
86. de Groot P. G., Derksen R. H., de Laat B. Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost: 2008; 34 4 347 355
87. de Groot P. G., Urbanus R. T. The future of antiphospholipid antibody testing. Semin Thromb Hemost: 2012; 38 4 412 420
88. Urbanus R. T., de Groot P. G. Antiphospholipid antibodies-we are not quite there yet. Blood Rev: 2011; 25 2 97 106
89. Whicher J. T., Ritchie R. F., Johnson A. M., et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem: 1994; 40 6 934 938 (Pubitemid 24166313)
90. Lippi G., Favaloro E. J., Plebani M. Direct-to-consumer testing: more risks than opportunities. Int J Clin Pract: 2011; 65 12 1221 1229
91. Plebani M., Lippi G. Direct-to-consumer genomewide profiling. N Engl J Med: 2011; 364 21 2074 2075, author reply 2075
92. Plebani M. The CCLM contribution to improvements in quality and patient safety. Clin Chem Lab Med: 2013; 51 1 39 46
93. Lippi G., Salvagno G. L., Montagnana M., Lima-Oliveira G., Guidi G. C., Favaloro E. J. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost: 2012; 38 6 565 575
94. Adcock Funk D. M., Lippi G., Favaloro E. J. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost: 2012; 38 6 576 585